Test of a copied growth-factor shot under the skin
This Phase 1 study checks how a “biosimilar” version of filgrastim works in healthy men given under the skin. It mainly aims to compare the body’s response (safety and how the drug behaves) rather than treat a disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a healthy male age 18 to 55 and able to sign the consent form
- Have a body weight between 60 and 100 kg and BMI between 18.5 and 29.9
- Test negative for coronavirus before starting
- Have no signs of illness and no flu-like symptoms in the 7 days before the start
- Avoid close contact with people who recently tested positive for coronavirus, and avoid living with higher-risk people
- Not have certain health conditions (like recent cancer, severe asthma, sickle cell disease, major allergies), and don’t take regular medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how an injected “copy” version of erythropoietin behaves in the blood in healthy volunteers. It’s mainly about measuring safety and blood-level changes, not treating an illness.
This Phase 3 study tests using filgrastim (a medicine that helps stem cells leave the bone marrow) to collect stem cells from unrelated donors for transplant. It focuses on donor safety and whether this collection method works well enough for transplantation.
This early (Phase 1) study tests whether giving a growth factor injection (rhu-G-CSF) to healthy volunteers can help collect whole blood for research. It looks at safety and whether the donated blood can be collected under specific health conditions.
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
This trial tests a new drug, Efbemalenograstim Alfa (a type of G-CSF), to prevent a drop in white blood cells (neutropenia) that can happen after chemotherapy combined with immunotherapy. It is for people with advanced lung or esophageal cancer who are at high risk for this complication.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.